Home > News & Opinion

News & Opinion

  • Guest blog: Drug zone
    26 October 2012
    Comments ( 1 )

    Rodent and stem cell models remain challenging for developing psychiatric drugs, says Michael Ehlers, chief scientific officer of neuroscience at Pfizer.

  • Genetics: More SHANK3 mutations in mild autism cases
    26 October 2012
    Comments ( 0 )

    Mutations in SHANK3, a leading autism risk gene, occur in roughly two percent of individuals with autism spectrum disorders, according to a study published 15 August in the European Journal of Human Genetics.

  • Autism Speaks launches scheme to develop drugs, devices
    25 October 2012
    Comments ( 0 )

    The research and advocacy organization Autism Speaks plans to launch a nonprofit arm that will fund companies to develop treatments for the disorder, Robert Ring, head of translational research for the organization, announced yesterday at the Autism Consortium Research Symposium in Boston.

  • Thomas Bourgeron: Pioneering rare paths in autism genetics
    25 October 2012
    Comments ( 0 )

    Thomas Bourgeron discovered the first rare mutation linked to non-syndromic autism, pointing to neuronal connections as prime drug targets.

  • New rules allow joint diagnosis of autism, attention deficit
    25 October 2012
    Comments ( 3 )

    About 30 percent of children with autism have symptoms of attention deficit hyperactivity disorder, but under current diagnostic guidelines they can only be diagnosed with one or the other. That’s about to change.